Secretory Clusterin Is a Marker of Tumor Progression Regulated by IGF-1 and Wnt Signaling Pathways

被引:1
|
作者
Zou, Yonglong [1 ]
Goetz, Eva M. [1 ]
Suzuki, Masatoshi [1 ]
Boothman, David A. [1 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dept Oncol, Program Cell Stress & Canc Nanomed, Dallas, TX 75390 USA
关键词
Clusterin; IGF-1; Wnt; TGF-beta(1); GSK3; beta; beta-catenin; TCF; APC; Egr-1; GROWTH-FACTOR-BETA; EPITHELIAL-MESENCHYMAL TRANSITIONS; GLYCOGEN-SYNTHASE KINASE-3; CELL-CELL ADHESION; NF-KAPPA-B; PROTEIN-KINASE; E-CADHERIN; CATENIN STABILITY; CANCER CELLS; ACTIVATION;
D O I
10.1007/978-4-431-88659-4_26
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Secretory clusterin (sCLU) is a pro-survival factor that can be induced by cellular stress, including ionizing radiation (IR), many cytotoxic agents, and during cellular replicative or low doses of stress-induced senescence. sCLU expression changes with tumor stage and grade in various types of cancer. Previously our laboratory found that sCLU was induced by IR through activation of the IGF-IR/Src/MEK/Erk/Egr-1 pathway. APC loss in Min-/- mice was also linked to elevated sCLU expression, especially in human colon cancer. We now find that Wnt signaling can cross talk with IGF-1 signaling to regulate sCLU expression. The cross talk between the IGF-1 and Wnt signaling pathways is very complex, not only because they share many components but also because they are delicately regulated by time, dose, and cell type. Both positive and negative feedback regulation loops regulate sCLU expression. Understanding these complicated signaling pathways will be essential for delineating the roles of Wnt, IGF-1, and sCLU expression in tumor progression, aging, and cancer, as well as in heart and Alzheimer's diseases aberrant where sCLU expression has been implicated.
引用
收藏
页码:204 / 211
页数:8
相关论文
共 50 条
  • [1] Notch signaling is regulated by IGF-1 in astrocytes
    Acaz-Fonseca, E.
    Sanchez-Gonzalez, R.
    Astiz, M.
    Arevalo, M. A.
    Garcia-Segura, L. M.
    [J]. JOURNAL OF NEUROCHEMISTRY, 2015, 134 : 102 - 102
  • [2] IGF-1 activates the P13K/AKT signaling pathway via upregulation of secretory clusterin
    Ma, Xiumei
    Bai, Yongrui
    [J]. MOLECULAR MEDICINE REPORTS, 2012, 6 (06) : 1433 - 1437
  • [3] Targeting IGF-1 signaling pathways in gynecologic malignancies
    Bruchim, Ilan
    Werner, Haim
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2013, 17 (03) : 307 - 320
  • [4] RAS AND IGF-1 SIGNALING PATHWAYS IN CARDIAC GROWTH AND HYPERTROPHY
    HUNTER, JJ
    LEMBO, G
    CHIEN, KR
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1994, : A45 - A45
  • [5] Genetic variation in insulin/IGF-1 signaling pathways and longevity
    Ziv, Elad
    Hu, Donglei
    [J]. AGEING RESEARCH REVIEWS, 2011, 10 (02) : 201 - 204
  • [6] Crosstalk between IGF-1 and myostatin signaling pathways in skeletal muscle
    Hao, Yanlei
    Wagner, Kathryn
    [J]. NEUROLOGY, 2007, 68 (12) : A3 - A3
  • [7] IGF-1 signaling and aging
    Holzenberger, M
    Kappeler, L
    De Magalhaes, C
    [J]. EXPERIMENTAL GERONTOLOGY, 2004, 39 (11-12) : 1761 - 1764
  • [8] Regulation of laminin expression and cell cycle progression by IGF-1 in renal mesangial cells: An examination of the intracellular signaling pathways
    Singh, Lalit P.
    Cheng, Davis W.
    Jiang, Yan
    [J]. DIABETES, 2006, 55 : A183 - A184
  • [9] IGF-1 regulates Ang II and VEGF signaling pathways in retinal neovascularization
    Li, F.
    Liu, Y.
    Ren, L.
    Sun, Q.
    Luo, Y. -X.
    [J]. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2018, 22 (19) : 6175 - 6180
  • [10] ATM-dependent IGF-1 induction regulates secretory clusterin expression after DNA damage and in genetic instability
    Goetz, E. M.
    Shankar, B.
    Zou, Y.
    Morales, J. C.
    Luo, X.
    Araki, S.
    Bachoo, R.
    Mayo, L. D.
    Boothman, D. A.
    [J]. ONCOGENE, 2011, 30 (35) : 3745 - 3754